Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval

JAMA Oncol. 2015 Oct;1(7):875-6. doi: 10.1001/jamaoncol.2015.1293.
No abstract available

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Data Interpretation, Statistical
  • Disease Progression
  • Disease-Free Survival
  • Drug Approval*
  • Female
  • Humans
  • Neoadjuvant Therapy* / adverse effects
  • Neoadjuvant Therapy* / mortality
  • Neoplasm Recurrence, Local
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration*

Substances

  • Antineoplastic Agents